Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

Winkler, Emma S., Gilchuk, Pavlo, Yu, Jinsheng, Bailey, Adam L., Chen, Rita E., Chong, Zhenlu, Zost, Seth J., Jang, Hyesun +12 more·2021·Cell
DOI 10.1016/j.cell.2021.02.026

Cited by (370)

Items 301–370 of 370

  1. Monocyte-eosinophil signaling axis promotes vaccine-mediated protection against SARS-CoV-2
    Kathryn M. Moore, Stephanie L. Foster, Meenakshi Kar, Katharine A. Floyd, Elizabeth J. Elrod, Mary E. K. Williams, Jacob W. Vander Velden, Madison Leigh Ellis, Ansa A. Malik, Bushra Wali et al. · 2025 · PLoS Pathogens
  2. Polyfunctional antibody signature defines protection in Andes hantavirus survival
    Felipe Bravo, Tybbysay P. Salinas, Camila Kossack, Jorge T. Gonzalez, Israel Giacaman, Claudio Quevedo, Sebastián Fuller, Farides Saavedra, Claudio Aguilera-Pérez, Felipe Aguilera et al. · 2026 · Frontiers in Immunology
  3. Multifaceted roles of Fcγ receptors in COVID-19 and vaccine responses.
    Abdellatif Bouayad · 2023 · PubMed Central
  4. Underappreciated layers of antibody-mediated immune synapse architecture and dynamics
    Benjamin S. Goldberg, Margaret E. Ackerman · 2024 · mBio
  5. Longitudinal humoral immunity against SARS-CoV-2 Spike following infection in individuals from Cameroon
    Mehdi Benlarbi, Dell-Dylan Kenfack, Katrina Dionne, Maxime Côté-Chenette, Guillaume Beaudoin-Bussières, Étienne Bélanger, Shilei Ding, Oumarou Goni Hamadama, Yannick F. Ngoume, Alexandra Tauzin et al. · 2025 · Virology
  6. Fc Functions and Anti-HIV Neutralizing Antibodies: A Perspective
    Hillary A. Vanderven, Stephen John Kent · 2025 · Current HIV Research
  7. Somatic hypermutation shapes the viral escape profile of SARS-CoV-2 neutralising antibodies
    Matthias Bruhn, Maureen A. Obara, Mariana González-Hernández, Wencke Reineking, Md. Abdus Salam, Monica Mirolo, Imke Hinrichs, AhmedElmontaser Mergani, Yannic C. Bartsch, Axel Schambach et al. · 2025 · EBioMedicine
  8. FcγRIIIa is a noncanonical costimulatory molecule for CD8 T cells
    Kevin Shuolong Kao, Nicole Loren Pihlstrom, Emily G. Niejadlik, Tineke Cantaert, Rafi Ahmed, Jeffrey V. Ravetch, Stylianos Bournazos · 2025 · Proceedings of the National Academy of Sciences
  9. Illuminating the Fc dependence of SARS-CoV-2 neutralization
    Joseph C. González, Taia T. Wang · 2021 · Immunity
  10. Unveiling a New Perspective on Distinguishing Omicron Breakthrough Cases and Postimmune COVID-19-Naive Individuals: Insights from Antibody Profiles
    Shihan Zhang, Chen Dong, Qian Zhen, Chao Shi, Hua Tian, Chuchu Li, Xiaoxiao Kong, Qigang Dai, Haodi Huang, Aidibai Simayi et al. · 2023 · Microbiology Spectrum
  11. BA.2 evasion of vaccine induced binding and functional non-neutralizing antibodies
    Yannic C. Bartsch, Deniz Cizmeci, Jaewon Kang, Hailong Gao, Wei Shi, Abishek Chandrashekar, Ai-ris Yonekura Collier, Bing Chen, Dan H. Barouch, Galit Alter · 2022 · medRxiv
  12. Intranasal vaccination of Syrian Hamsters with ChAd-SARS-CoV-2-S disrupts airborne transmission cycles of SARS-CoV-2
    Adrianus C. M. Boon, Tamarand L. Darling, Houda Harastani, Astha Joshi, Traci L. Bricker, Kuljeet Seehra, Ahmed O. Hassan, Michael Diamond · 2023 · Research Square
  13. BNT162b2 COVID-19 vaccination elicits the expansion of CD16+CD8+ T cells endowed with natural killer cell features
    Claudia De Pasquale, Fabiana Drommi, Alessia Calabrò, Cirino Botta, Giacomo Sidoti Migliore, Paolo Carrega, Grazia Vento, Amirhossein Gaeini, Gaetana Pezzino, Josè Freni et al. · 2025 · Journal of Allergy and Clinical Immunology
  14. Interaction of the endogenous antibody response with activating FcγRs enhance control of Mayaro virus through monocytes
    Megan M. Dunagan, Nathânia Dábilla, Colton M McNinch, Jason M. Brenchley, Patrick Dolan, Julie M. Fox · 2025 · PLoS Pathogens
  15. More antibodies are not always better: Fc effector functions play a critical role in SARS-CoV-2 infection and protection
    Alberto Rubio‐Casillas, Elrashdy M Moustafa Mohamed Redwan, Vladimir Nikolaevich Uversky · 2025 · Progress in molecular biology and translational science
  16. Fc-Modified Antibody in Hospitalized Severe COVID-19 Patients
    Felipe Dal‐Pizzol, Suzana Margareth Lobo, CHRISTOPHER J. LUCASTI, Adam Abdul Hakeem Baidoo, Huo Su, Zhanghua Lan, Liangzhi Xie · 2025 · Vaccines
  17. Patient and donor antibody profiles in early COVID-19 convalescent plasma therapy in the COnV-ert trial
    Andrea Alemany, Dan Ouchi, Edwards Pradenas, Ruth Aguilar, Marta Vidal, Alfons Jiménez, Pere Millat-Martínez, Marc Corbacho‐Monné, Clara Suñer, Quique Bassat et al. · 2025 · Frontiers in Immunology
  18. Reduced Fc-mediated antibody responses after COVID-19 mRNA vaccination in a cohort of people living with HIV-1
    Jéromine Klingler, Priyanka Gadam Rao, Juan C. Bandrés, Ismael Pena, Katherine Bolanos Roldan, Gagandeep Singh, Brian Monahan, Charles Gleason, Yuexing Chen, Stefan Slamanig et al. · 2025 · Scientific Reports
  19. Viral glycoprotein-mediated entry and antibody-mediated immunity in HIV-1 and SARS-CoV-2 infection
    Michael W. Grunst, Wenwei Li, Walther Mothes · 2026 · Frontiers in Immunology
  20. Evaluation of the efficacy of four anti-SARS-CoV-2 antibodies after vaccination using kits from two manufacturers: A prospective, longitudinal, cohort study at 11 serial time points within 160 days
    Lin Xie, Qiu‐Yan Xu, Xin‐Qi Zheng, Jian-Hang Xue, Jianjun Niu, Tian‐Ci Yang · 2022 · International Immunopharmacology
  21. Mid-titer human convalescent plasma administration results in suboptimal prophylaxis against SARS-CoV-2 infection in rhesus macaques
    Brandon J. Beddingfield, Nicholas J. Maness, Skye Spencer, Jay Rappaport, Pyone P. Aye, Kasi Russell‐Lodrigue, Lara A. Doyle‐Meyers, Robert V. Blair, Hongmei Gao, David C. Montefiori et al. · 2023 · Frontiers in Immunology
  22. Convalescent human IgG, but not IgM, from COVID-19 survivors confers dose-dependent protection against SARS-CoV-2 replication and disease in hamsters
    Hannah A. D. King, Vincent Dussupt, Letzibeth Mendez-Rivera, Bonnie M. Slike, Ursula Tran, Nathan D. Jackson, Erica K. Barkei, Michelle Zemil, Emily Tourtellott‐Fogt, Caitlin H. Kuklis et al. · 2023 · Frontiers in Immunology
  23. A Retrospective Observational Study of Neurological Manifestations in COVID-19 (SON-CoV)
    Neetu Ramrakhiani, Neeraj Bhutani, Deepak Chaudhary, Pooja Parab, Karni Singh, Priya Agrawal, Vikas K Gupta · 2022 · Journal of the Association of Physicians of India
  24. Holistic in silico developability assessment of novel classes of small proteins using publicly available sequence-based predictors
    Daniel A. M. Pais, Jan-Peter A. Mayer, Karin Felderer, Maria B. Batalha, Timo Eichner, Sofia T. Santos, Raman Kumar, Sandra Regina Augusta da Silva, Hitto Kaufmann · 2024 · Journal of Computer-Aided Molecular Design
  25. Sequence Matters: Primary COVID-19 Vaccination after Infection Elicits Similar Anti-spike Antibody Levels, but Stronger Antibody Dependent Cell-mediated Cytotoxicity than Breakthrough Infection
    Kayla A. Holder, Danielle P. Ings, Kathleen E. Fifield, David A Barnes, Keeley A. Barnable, Debbie O. A. Harnum, Rodney S. Russell, Michael D. Grant · 2024 · The Journal of Immunology
  26. Multiple exposures to SARS-CoV-2 Spike enhance cross-reactive antibody-dependent cellular cytotoxicity against SARS-CoV-1
    Guillaume Beaudoin-Bussières, Alexandra Tauzin, Katrina Dionne, Omar El Ferri, Mehdi Benlarbi, Catherine Bourassa, Halima Medjahed, Renée Bazin, Marceline Côté, Andrés Finzi · 2025 · Virology
  27. A SARS-CoV-2-ellenes antitestekkel végzett terápia helye a COVID–19 kezelésében
    Ákos Fábián · 2021 · Orvosi Hetilap
  28. Infectivity-enhancing antibodies against SARS-CoV-2
    2021 · Uirusu
  29. Acquisition of resistance to wild-type spike-immune sera by emerging SARS-CoV-2 variants
    Hisashi Arase, Yafei Liu, Noriko Arase, Jun-ichi Kishikawa, Mika Hirose, Songling Li, Asa Tada, Sumiko Matsuoka, Akemi Arakawa, Kanako Akamatsu et al. · 2021 · Research Square
  30. Preclinical Efficacy of IMM-BCP-01, a Highly Active Patient-Derived Anti-SARS-CoV-2 Antibody Cocktail
    Pavel A. Nikitin, Jillian M. DiMuzio, John P. Dowling, Nirja B. Patel, Jamie L. Bingaman, Baron C. Heimbach, Noeleya Henriquez, Chris Nicolescu, Antonio M Polley, Eden L. Sikorski et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  31. Macaque-human differences in SARS-CoV-2 Spike antibody response elicited by vaccination or infection
    Alexandra C. Willcox, Kevin Sung, Meghan E. Garrett, Jared Galloway, Megan A. O’Connor, Jesse H. Erasmus, Jennifer K. Logue, David W. Hawman, Helen Y. Chu, Kim J. Hasenkrug et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  32. Altered affinity to ACE2 and reduced Fc functional antibodies to SARS-CoV-2 RBD variants
    Ebene R. Haycroft, Samantha K. Davis, Pradhipa Ramanathan, Ester López, Ruth A Purcell, Li Lynn Tan, Phillip Pymm, Bruce D. Wines, Philip Mark Hogarth, Adam K. Wheatley et al. · 2022 · medRxiv
  33. Protective non-neutralizing mAbs Ab94 and Ab81 retain high-affinity and potent Fc-mediated function against SARS-CoV-2 variants from Omicron to XBB1.5
    Arman Izadi, Magdalena Godzwon, Mats Ohlin, Pontus Nordenfelt · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  34. Activating FcγRs on monocytes are necessary for optimal Mayaro virus clearance
    Megan M. Dunagan, Nathânia Dábilla, Colton M McNinch, Jason M. Brenchley, Patrick Dolan, Julie Fox · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  35. Humoral immune responses against seasonal coronaviruses predict efficiency of SARS-CoV-2 spike targeting, FcγR activation, and corresponding COVID-19 disease severity
    Jose L. Garrido, Matías A. Medina, Felipe Bravo, S. McGee, F. Fuentes, M. Calvo, James Bowman, C. Bahl, M. I. Barria, R. A. Brachman et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  36. A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in rhesus macaques
    Ronald R. Cobb, Joseph P. Nkolola, P. Gilchuk, A. Chandrashekar, R. V. House, Christopher G. Earnhart, N. Dorsey, Svetlana A. Hopkins, Doris M. Snow, Rita E. Chen et al. · 2021 · bioRxiv
  37. Antibody avidity and multi-specificity combined to confer protection against SARS-CoV-2 and resilience against viral escape
    Clare Burn Aschner, Krithika Muthuraman, Iga Kucharska, Hong Cui, Katherine Prieto, Manoj S. Nair, Maple Wang, Yaoxing Huang, Natasha Christie-Holmes, Betty Poon et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  38. Data from Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies
    David J. Chung, Gunjan L. Shah, Sean M. Devlin, Lakshmi V. Ramanathan, Sital Doddi, Melissa S. Pessin, Elizabeth Hoover, LeeAnn T. Marcello, Jennifer C. Young, Sawsan R. Boutemine et al. · 2023
  39. Antibody effector functions are required for broad and potent protection of neonates from herpes simplex virus infection
    Matthew D. Slein, Iara M. Backes, Callaghan R. Garland, Natasha S. Kelkar, David A. Leib, Margaret E. Ackerman · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  40. Research progress on the neutralizing antibody response to SARS-CoV-2
    Shishan Teng, Xiaowang Qu · 2023 · Scientia Sinica Vitae
  41. Fc-dependent functional activity of ChAdOx1-S and CoronaVac vaccine-induced antibodies to the SARS-CoV-2 spike protein
    Alexander W. Harris, Liriye Kurtovic, Jeane Nogueira, Isabel Cristina da Silva Bouzas, D. Herbert Opi, Bruce D. Wines, Philip Mark Hogarth, Pantelis Poumbourios, Heidi E. Drummer, Clarissa Valim et al. · 2023 · medRxiv
  42. Engineered Therapeutic Antibody Against SARS-CoV-2
    Monrat Chulanetra · 2023 · Current Clinical Microbiology Reports
  43. The Covid-19 and TB Syndemic: Differences and Similarities
    Stefan H. E. Kaufmann, Alan Sher, Alex Sigal, Birgit Sawitzki · 2023 · Frontiers research topics
  44. RBD-Protein/Peptide Vaccine UB-612 Elicits Mucosal and Fc-Mediated Antibody Responses against SARS-CoV-2 in Cynomolgus Macaques
    Shixia Wang, Farshad Guirakhoo, Sivakumar Periasamy, Valorie Ryan, Jonathan Wiggins, Chandru Subramani, Brett A. Thibodeaux, Jaya Sahni, Michael S. Hellerstein, Natalia A. Kuzmina et al. · 2023 · Vaccines
  45. The use of immunoglobulins and monoclonal antibodies against COVID-19
    E. E. Popadyuk, Tatiana E. Sizikova, A. L. Khmelev, M. A. Timofeev, Vitaliy N. Lebedev, Sergey V. Borisevich · 2024 · Problems of Virology
  46. Efeitos do Casirivimabe e Imdevimabe no tratamento do COVID-19: uma revisão integrativa
    Paulo Vytor Cardoso Nobre, Guilherme Augusto Grangeiro Amorim, Abrahao Verçosa Amorim Filho, Laís Acioli Lins, João Victor Nunes Cadete, Ray de Lima Coutinho Costa, Maria Luísa Vieira Cuyabano Leite, Josivaldo De Araújo Alves Júnior, Caio César Gusmão Costa Coutinho, Luis Guilherme Gomes de Athayde et al. · 2024 · Contribuciones a las Ciencias Sociales
  47. ACE2 decoy Fc-fusions and bi-specific killer engager (BiKEs) require Fc engagement for in vivo efficacy against SARS-CoV-2
    Jenna K. Dick, Dustin M. Hicks, Venkatramana Divana Krishna, Jules A. Sangala, Benjamin T. Zandstra, Carly Baehr, J. Sjef Verbeek, Mark Steven Cragg, Maxim C.‐J. Cheeran, Marco Pravetoni et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  48. Unveiling unique effector function-related bulk antibody profiles in long-term hemodialysis patients following COVID-19 mRNA booster vaccination
    Chia-Yi Chou, Chung‐Yi Cheng, Chih‐Hsin Lee, Makoto Kuro‐o, Tso-Hsiao Chen, San‐Yuan Wang, Yung‐Kun Chuang, Yun-Jung Yang, Yun-Hsuan Lin, I‐Lin Tsai · 2024 · Journal of Microbiology Immunology and Infection
  49. Study of the immunogenicity, efficacy and safety of recombinant RBD SARS-CoV-2 vaccine with CpG adjuvant in rodent, non-rodent and Maccaca fascicularis using Indonesian Strain Virus
    Nur Amalia Limeilati, Reviany V. Nidom, Trilokita Tunjung Sari, Nurvita Putih Kusumarahayu, Siti V. Fransiska, Setyarina Indrasari, Afrillia Nuryanti Garmana, Dhyan K. Ayuningtyas, Gembong S. Nugroho, Darsono Darsono et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  50. T‐Cell‐Dependent Bispecific IgGs Protect Aged Mice From Lethal SARS‐CoV‐2 Infection
    Wenyan Fu, Wei jin Zhang, Zedong You, Guangyao Li, Chuqi Wang, Changhai Lei, Jian Zhao, Jin Lin Hou, Shi Hu · 2025 · Advanced Science
  51. Severe Acute Respiratory Syndrome Coronavirus 2 Immunology and Coronavirus Disease 2019 Clinical Outcomes
    Aljawharah Alrubayyi, Hsinyen Huang, Gaurav D. Gaiha · 2025 · Infectious Disease Clinics of North America
  52. Epitope-driven polyfunctional divergence of SARS-CoV-2 RBD antibodies
    Pierre Rosenbaum, Cyril Planchais, Timothée Bruel, Maxime Beretta, Isabelle Staropoli, William Bolland, Florence Guivel‐Benhassine, Delphine Planas, French COVID Cohort Study Group, CORSER Study Group et al. · 2026 · iScience
  53. Structural and Functional Characterization of Anti-SARS-CoV-2 Spike Monoclonal Antibodies Produced via Bicistronic Expression in CHO Cells
    Federico Francisco Marsili, Fernanda Bittencourt de Aquino, Hiam R. S. Arruda, Mayra A. Marques, Kátia Maria dos Santos Cabral, Marcius S. Almeida, Guilherme A. P. de Oliveira, Andréa Queiróz Maranhão, Renato Sampaio Carvalho, Leda R. Castilho · 2025 · Antibodies
  54. Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variants
    Shilei Ding, Derek Yang, Irfan Ullah, Ling Niu, Matthew Unger, Marco Aurelio Díaz-Salinas, Monika Chandravanshi, Fei Zhou, Guillaume Beaudoin-Bussières, Mehdi Benlarbi et al. · 2025 · Journal of Virology
  55. Infection Of Rhesus Macaques With O’nyong-nyong Virus UVIR-O804 Recapitulates Key Aspects of Human Clinical Disease
    Hannah K. Jaeger, Michael C. Denton, Takeshi F. Andoh, Craig N. Kreklywich, Lina Gao, Lydia J. Pung, Zachary J. Streblow, Ann McMonigal, Karina Ray, Brayden Graves et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  56. Additional file 1 of Cell-based passive immunization for protection against SARS-CoV-2 infection
    Evan Sawula, Shane Miersch, Jong, Eric D., Li, Chengjin, Chou, Fang-Yu, Jean Kit Tang, Reza Saberianfar, Harding, Jeffrey, Sidhu, Sachdev S., Nagy, Andras · 2024 · Figshare
  57. Determinants of natural killer cell-mediated antibody dependent cellular cytotoxicity in SARS-CoV-2 antibodies
    Delphine M Depierreux, F. Ruiz, M. Lilly, J. Guenthoer, V. Chohan, J. Overbaugh · 2026 · PLoS Pathogens
  58. Evaluating varicella-zoster virus vaccine immunogenicity through Fc-mediated antibody functions: the roles of ADCP and ADCC
    Sivilay Xayaheuang, Ji‐Young Hwang, Yunhwa Kim, Kyung-Min Lee, Seok-Tae Choi, Eun-Jeong Jang, Ji-Soo Lim, Ji Young Bang, Han Sol Lee, Ok Sarah Shin et al. · 2026 · npj Vaccines
  59. Caractérisation des activités antivirales des anticorps anti-VIH-1 et anti-SARS-CoV-2
    Jérémy Dufloo · 2021 · theses.fr (ABES)
  60. Caractérisation de la réponse lymphocytaire B mémoire contre le SARS-CoV-2 après infection ou vaccination
    Aurélien Sokal · 2022 · theses.fr (ABES)
  61. Fc-engineered antibodies enhance protection against SARS-CoV-2 lung infection and inflammation
    Samantha Mackin, Chieh-Yu Liang, Courtney E. Karl, Maksim Kleverov, Mehak Zahoor Khan, Thendral Selvam, Matthias Mack, Galit Alter, Barbara Guarino, Davide Corti et al. · 2026 · mBio
  62. Mucosal Delivery of Recombinant SARS-CoV-2 Spike Receptor-Binding Domain Antigen Containing Immune-Stimulating Peptides Induces Protective Immune Responses Against Viral Infection in huACE2 Mice
    Byeol-Hee Cho, Ju Kim, Yong‐Suk Jang · 2026 · Vaccines
  63. From passive protection to lasting immunity: the potential vaccinal effect of antiviral monoclonal antibodies
    Sofia Sedó-Nicolaisen, Therese Nordby Larsen, Jesper Damsgaard Gunst, Ole Schmeltz Søgaard · 2026 · International Journal of Infectious Diseases
  64. Coupling dead cell recognition to Fcγ receptors augments anticancer immunity
    Tomas Castro‐Dopico, Cécile Piot, Michael D. Buck, Lucía Gandullo‐Sánchez, Kok Haw Jonathan Lim, Gerone A. Gonzales, Nikita Rosendahl, Oliver Schulz, William Stainier, Brian Vash et al. · 2026 · Nature Cancer
  65. Infection of Rhesus Macaques with O’nyong-nyong virus UVRI-0804 recapitulates key aspects of human clinical disease
    Hannah K. Jaeger, Michael C. Denton, Takeshi F. Andoh, Craig N. Kreklywich, Lina Gao, Lydia J. Pung, Zachary J. Streblow, Ann McMonigal, Karina Ray, Brayden Graves et al. · 2026 · PLoS neglected tropical diseases
  66. The Role of Human Viral Entry Receptor Mouse Models in Advancing Antiviral Antibodies and Vaccines
    Na Zuo, Xin Zheng, Rameez Ishaq, Deshan Ren, Ao Hu · 2026 · Vaccines
  67. ACE2 decoy Fc-fusions and bispecific killer engagers require Fc engagement for in vivo efficacy against SARS-CoV-2.
    Jenna K. Dick, V. Krishna, D. Hicks, Jules A. Sangala, Robert J. Oldham, Benjamin T. Zandstra, C. Baehr, J. Verbeek, M. Cragg, M. Pravetoni et al. · 2026 · Journal of Immunology
  68. Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus
    Michael Diamond · 2025 · ImmPort
  69. Antibodies elicited in humans upon chimeric hemagglutinin-based influenza virus vaccination confer FcgR-dependent protection in vivo
    Jeffrey Ravetch · 2024 · ImmPort
  70. Protective activity of mRNA vaccines
    Florian Krammer · 2024 · ImmPort